Newsfile Corp
29 Jun 2026, 10:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Grail's NHS-Galleri Trial failed to observe a statistically significant reduction in Stage III-IV cancers, causing the stock price to drop over 50% on February 19, 2026. — The failure of a primary clinical endpoint for a core product leads to massive loss of valuation and undermines the company's commercial thesis.
-0.90Grail and its executives are facing a class action lawsuit alleging they made false or misleading statements regarding the probability of achieving the NHS-Galleri trial's primary endpoint. — Securities litigation creates significant legal liability and overhang, though the impact is secondary to the actual trial failure.
-0.40Which stocks this story touches
The company is facing a class action lawsuit following a 50% stock price drop and failure to meet trial endpoints.
Continue reading
6 related stories
Top 3 movers · tap to explore
Mentioned in an investor alert regarding an opportunity to lead a class action lawsuit.
Mentioned in an investor notice regarding an opportunity to lead a class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
